Oral liquid with chemotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests an oral liquid medicine called BLEX 404 combined with standard chemotherapy (pemetrexed and cisplatin) for people with advanced non-small cell lung cancer that has not spread to the brain or caused symptoms. The goal is to see if the combination is safe and more effective than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 70 years old.
- You have been diagnosed with advanced or metastatic non-squamous non-small cell lung cancer that has not been treated yet.
- Your cancer does not have an EGFR gene mutation (EGFR wild-type).
- Your doctor plans to give you the standard chemotherapy drugs pemetrexed and cisplatin.
- You are willing and able to follow the study plan and give written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
This study tests a new combination of drugs (SYHX2011, carboplatin, and an immunotherapy called enlonstobart) as the first treatment for advanced squamous lung cancer that is PD-L1 positive. The goal is to see if this combination helps shrink tumors and slow cancer growth.
This trial compares pembrolizumab (an immunotherapy drug) given alone versus combined with chemotherapy for women with advanced non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if adding chemotherapy improves outcomes.
Hear when a new Nonsquamous Nonsmall Cell Neoplasm of Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.